We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Bet on 5 Stocks with Upgraded Broker Ratings Right Now
Given the current upbeat market performance, it is difficult for retail investors to choose stocks independently and generate solid returns. For this, one has to understand the fundamentals of the company and try to place them against the current economic background to figure out how the stock may fare as an investment.
One way to cut short this task is to follow brokers' recommendations. Stocks like Wolverine World Wide, Inc., BioMarin Pharmaceutical Inc., Datadog, Inc., Progressive Corp. and Klaviyo, Inc. are worth betting on.
As brokers directly communicate with top management, they have more insight into what is happening in a particular company. They assess a company's publicly available documents and even attend conference calls.
Brokers have more understanding of the overall sector and industry. They place company fundamentals against the current economic backdrop to determine how a particular stock will fare as an investment.
When brokers upgrade a stock, one can easily rely on their judgment. Yet, depending on broker upgrades is not enough to build your investment portfolio. Several other factors should be taken into account to ensure steady returns.
5 Stocks with Upgraded Brokers Ratings
Based in Rockford, MI, Wolverine is engaged in the designing, manufacturing and distribution of a wide variety of casual as well as active apparel and footwear. WWW also manufactures children's footwear and specially designed boots and accessories for industrial purposes.
Wolverine's 2024 earnings are expected to skyrocket 1600% year over year. WWW, sporting a Zacks Rank #1, has witnessed a 12.5% upward revision in broker ratings over the past four weeks.
Headquartered in San Rafael, CA, BioMarin focuses on the development and commercialization of treatments for life-threatening severe medical conditions, mainly for children. BMRN has a collaboration agreement with Sanofi's subsidiary, Genzyme, for Aldurazyme. Genzyme is BioMarin's sole customer for Aldurazyme and is responsible for marketing and selling Aldurazyme to third parties.
BioMarin's 2024 earnings are projected to grow at the rate of 54.3% on a year-over-year basis. The company, carrying a Zacks Rank #2 at present, has witnessed an 8% upward revision in broker ratings over the past four weeks.
Datadog, based in New York, is a monitoring and analytics platform for developers, IT operations teams and business users in the cloud age. DDOG's business runs around its portfolio of more than 400 out-of-the-box integrations, including public cloud, private cloud, on-premise hardware, databases and third-party software.
Datadog's 2024 earnings are expected to jump 22.7%. DDOG, carrying a Zacks Rank #2 at present, has witnessed a 2.6% upward revision in broker ratings in the past four weeks.
Headquartered in Tampa, FL, Progressive Corp is one of the major auto insurers in the country. PGR is a leading independent agency writer of private passenger auto coverage and the market leader for motorcycle products.
Progressive Corp's 2024 earnings are projected to surge 99.7% on a year-over-year basis. PGR, carrying a Zacks Rank #2 at present, has witnessed a 10% upward revision in broker ratings over the past four weeks.
Based in Boston, MA, Klaviyo provides a software-as-a-service platform globally. It offers Klaviyo, a cloud-native platform for data store, segmentation engine, campaigns and flows, and messaging infrastructure.
Klaviyo's 2024 earnings are expected to rise 33.3% year over year. KVYO, carrying a Zacks Rank #2, has witnessed a 6.3% upward revision in broker ratings over the past four weeks.
Get the remaining stock on the list and start putting this and other ideas to the test. It can all be done with the Research Wizard stock picking and backtesting software.
The Research Wizard is a great place to begin. It's easy to use. Everything is in plain language. And it's very intuitive. Start your Research Wizard trial today. And the next time you read an economic report, open up the Research Wizard, plug your finds in, and see what gems come out.
Disclosure: Officers, directors and/or employees of Zacks Investment Research may own or have sold short securities and/or hold long and/or short positions in options that are mentioned in this material. An affiliated investment advisory firm may own or have sold short securities and/or hold long and/or short positions in options that are mentioned in this material.
About Screen of the Week
Zacks.com created the first and best screening system on the web earning the distinction as the "#1 site for screening stocks" by Money Magazine. But powerful screening tools is just the start. That is why Zacks created the Screen of the Week to highlight profitable stock picking strategies that investors can actively use.
Strong Stocks that Should Be in the News
Many are little publicized and fly under the Wall Street radar. They're virtually unknown to the general public. Yet today's 220 Zacks Rank #1 "Strong Buys" were generated by the stock-picking system that has more than doubled the market from 1988 through 2016. Its average gain has been a stellar +25% per year. See these high-potential stocks free >>.
Follow us on Twitter: https://www.twitter.com/zacksresearch
Join us on Facebook: https://www.facebook.com/ZacksInvestmentResearch
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Zacks.com provides investment resources and informs you of these resources, which you may choose to use in making your own investment decisions. Zacks is providing information on this resource to you subject to the Zacks "Terms and Conditions of Service" disclaimer. www.zacks.com/disclaimer.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performancefor information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Zacks.com featured highlights include Wolverine World Wide, BioMarin Pharmaceutical, Datadog, Progressive and Klaviyo
For Immediate Release
Chicago, IL – September 4, 2024 – Stocks in this week’s article are Wolverine World Wide, Inc. (WWW - Free Report) , BioMarin Pharmaceutical Inc. (BMRN - Free Report) , Datadog, Inc. (DDOG - Free Report) , Progressive Corp. (PGR - Free Report) and Klaviyo, Inc. (KVYO - Free Report) .
Bet on 5 Stocks with Upgraded Broker Ratings Right Now
Given the current upbeat market performance, it is difficult for retail investors to choose stocks independently and generate solid returns. For this, one has to understand the fundamentals of the company and try to place them against the current economic background to figure out how the stock may fare as an investment.
One way to cut short this task is to follow brokers' recommendations. Stocks like Wolverine World Wide, Inc., BioMarin Pharmaceutical Inc., Datadog, Inc., Progressive Corp. and Klaviyo, Inc. are worth betting on.
As brokers directly communicate with top management, they have more insight into what is happening in a particular company. They assess a company's publicly available documents and even attend conference calls.
Brokers have more understanding of the overall sector and industry. They place company fundamentals against the current economic backdrop to determine how a particular stock will fare as an investment.
When brokers upgrade a stock, one can easily rely on their judgment. Yet, depending on broker upgrades is not enough to build your investment portfolio. Several other factors should be taken into account to ensure steady returns.
5 Stocks with Upgraded Brokers Ratings
Based in Rockford, MI, Wolverine is engaged in the designing, manufacturing and distribution of a wide variety of casual as well as active apparel and footwear. WWW also manufactures children's footwear and specially designed boots and accessories for industrial purposes.
Wolverine's 2024 earnings are expected to skyrocket 1600% year over year. WWW, sporting a Zacks Rank #1, has witnessed a 12.5% upward revision in broker ratings over the past four weeks.
Headquartered in San Rafael, CA, BioMarin focuses on the development and commercialization of treatments for life-threatening severe medical conditions, mainly for children. BMRN has a collaboration agreement with Sanofi's subsidiary, Genzyme, for Aldurazyme. Genzyme is BioMarin's sole customer for Aldurazyme and is responsible for marketing and selling Aldurazyme to third parties.
BioMarin's 2024 earnings are projected to grow at the rate of 54.3% on a year-over-year basis. The company, carrying a Zacks Rank #2 at present, has witnessed an 8% upward revision in broker ratings over the past four weeks.
Datadog, based in New York, is a monitoring and analytics platform for developers, IT operations teams and business users in the cloud age. DDOG's business runs around its portfolio of more than 400 out-of-the-box integrations, including public cloud, private cloud, on-premise hardware, databases and third-party software.
Datadog's 2024 earnings are expected to jump 22.7%. DDOG, carrying a Zacks Rank #2 at present, has witnessed a 2.6% upward revision in broker ratings in the past four weeks.
Headquartered in Tampa, FL, Progressive Corp is one of the major auto insurers in the country. PGR is a leading independent agency writer of private passenger auto coverage and the market leader for motorcycle products.
Progressive Corp's 2024 earnings are projected to surge 99.7% on a year-over-year basis. PGR, carrying a Zacks Rank #2 at present, has witnessed a 10% upward revision in broker ratings over the past four weeks.
Based in Boston, MA, Klaviyo provides a software-as-a-service platform globally. It offers Klaviyo, a cloud-native platform for data store, segmentation engine, campaigns and flows, and messaging infrastructure.
Klaviyo's 2024 earnings are expected to rise 33.3% year over year. KVYO, carrying a Zacks Rank #2, has witnessed a 6.3% upward revision in broker ratings over the past four weeks.
Get the remaining stock on the list and start putting this and other ideas to the test. It can all be done with the Research Wizard stock picking and backtesting software.
The Research Wizard is a great place to begin. It's easy to use. Everything is in plain language. And it's very intuitive. Start your Research Wizard trial today. And the next time you read an economic report, open up the Research Wizard, plug your finds in, and see what gems come out.
Click here to sign up for a free trial of the Research Wizard today.
For the rest of this Screen of the Week article please visit Zacks.com at: https://www.zacks.com/stock/news/2330202/bet-on-these-5-stocks-with-upgraded-broker-ratings-right-now
Disclosure: Officers, directors and/or employees of Zacks Investment Research may own or have sold short securities and/or hold long and/or short positions in options that are mentioned in this material. An affiliated investment advisory firm may own or have sold short securities and/or hold long and/or short positions in options that are mentioned in this material.
About Screen of the Week
Zacks.com created the first and best screening system on the web earning the distinction as the "#1 site for screening stocks" by Money Magazine. But powerful screening tools is just the start. That is why Zacks created the Screen of the Week to highlight profitable stock picking strategies that investors can actively use.
Strong Stocks that Should Be in the News
Many are little publicized and fly under the Wall Street radar. They're virtually unknown to the general public. Yet today's 220 Zacks Rank #1 "Strong Buys" were generated by the stock-picking system that has more than doubled the market from 1988 through 2016. Its average gain has been a stellar +25% per year. See these high-potential stocks free >>.
Follow us on Twitter: https://www.twitter.com/zacksresearch
Join us on Facebook: https://www.facebook.com/ZacksInvestmentResearch
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Contact: Jim Giaquinto
Company: Zacks.com
Phone: 312-265-9268
Email: pr@zacks.com
Visit: https://www.zacks.com/
Zacks.com provides investment resources and informs you of these resources, which you may choose to use in making your own investment decisions. Zacks is providing information on this resource to you subject to the Zacks "Terms and Conditions of Service" disclaimer. www.zacks.com/disclaimer.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performancefor information about the performance numbers displayed in this press release.